Abstracts tagged "Cardiovascular disease"

Abstract Number: 2212 • 2014 ACR/ARHP Annual Meeting
Serum Adipokines in Dermatomyositis: Correlation with Risk Factors Associated to Cardiovascular Diseases and Metabolic Syndrome
Marilda Guimarães Silva, Suzana Beatriz Veríssimo de Mello and Samuel Katsuyuki Shinjo, Rheumatology, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil
Background/Purpose: Adipokines are a group of cytokines produced by adipose tissue, which include adiponectin, resistin and leptin. The adiponectin has anti-diabetic, anti-inflammatory and anti-atherogenic effects,…
Abstract Number: 1441 • 2014 ACR/ARHP Annual Meeting
Accelerated Aging in DMARD and Treatment Naive Early Rheumatoid Arthritis Patients Measured By a Stem Cell Assay Is Associated with Increased LDL and Is Linked to Impaired Cardiopulmonary Function
Torkell Ellingsen^1,2,3, Henriette Jørgensen⁴, Dino Demirovic⁴, Lone Deibjerg⁵, Frank Andersen⁵, Agnete Hedemann-Andersen⁵, Brian Bridal Løgstrup^5,6 and Suresh Rattan⁴, ¹Diagnostic Centre Region, Hospital Silkeborg Denmark, Odense, Denmark, ²The Danish National Registry DANBIO, Odense, Denmark, ³Department of Rheumatology, Odense University Hospital, Denmark, Odense, Denmark, ⁴Laboratory of Cellular Ageing, Institute of Molecular Biology and Genetics, Århus University, Århus, Denmark, ⁵Diagnostic Centre Region, Hospital Silkeborg Denmark, Silkeborg, Denmark, ⁶Cardiology, Skejby Hospital, Århus Universityhosital, Århus, Denmark
Background/Purpose: The cardiovascular comorbidity seen in early treatment naive rheumatoid arthritis (RA) can be considered as an aspect of ´´accelerated aging``. Methods: We investigated cell…
Abstract Number: 1163 • 2014 ACR/ARHP Annual Meeting
Predictors of Cholesterol and Lifestyle Discussions in Rheumatoid Arthritis Visits: Impact of Perceived RA Control and Comparison with Other Prevention Topics
Christie M. Bartels¹, Joanna Wong², Heather Johnson³, Katya Voelker⁴ and Maureen Smith⁵, ¹Rheumatology/Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, ²Tufts University School of Medicine, Boston, MA, ³Cardiology/Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, ⁴Univ of Wisconsin School of Medicine and Public Health, Madison, AA, ⁵Population Health Sciences, University of Wisconsin School of Medicine and Public Health, Madison, WI
Background/Purpose: Experts recommend discussing modifiable cardiovascular disease (CVD) risk factors in RA visits. We examined the predictors of discussions about cholesterol and or lifestyle (weight,…
Abstract Number: 489 • 2014 ACR/ARHP Annual Meeting
Rosuvastatin Improves Arterial Stiffness in Patients with Inflammatory Joint Diseases
Eirik Ikdahl¹, Silvia Rollefstad¹, Jonny Hisdal², Inge C. Olsen³, Ingar Holme⁴, Terje R. Pedersen⁵, Tore Kvien⁶ and Anne Grete Semb¹, ¹Preventive Cardio-Rheuma clinic, Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ²Section of Vascular Investigations, Oslo University Hospital Aker, Oslo, Norway, ³Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁴Department of biostatistics, epidemiology and health economics, Oslo University Hospital, Oslo, Norway, ⁵Faculty of Medicine, University of Oslo, Oslo, Norway, ⁶Dept of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway
Background/Purpose Arterial stiffness, as pulse wave velocity (PWV) and augmentation index (AIx) has emerged as early risk markers of cardiovascular disease (CVD) in patients with…
Abstract Number: 2217 • 2014 ACR/ARHP Annual Meeting
Ultrasonography Analysis of Carotid Parameters in Patients with Idiopathic Inflammatory Myopaties: Correlation with Demographic Profile and Disease Activity
Simone Barsotti¹, Maria Aurora Morales², Rosaria Talarico³, Claudia Ferrari¹, Nicole Di Lascio², Anna d'Ascanio¹, Elisabetta Bianchini², Stefano Bombardieri³ and Rossella Neri¹, ¹Rheumatology Unit, University of Pisa, Pisa, Italy, ²Institute of Clinical Physiology, CNR, Pisa, Italy, ³Rheumatology Unit, Pisa, Italy
Background/Purpose Subclinical cardiovascular (CV) involvement is frequent in patients with idiopathic inflammatory myositis (IIM). Growing interest exists on the role of markers of subclinical CV…
Abstract Number: 1440 • 2014 ACR/ARHP Annual Meeting
Asymptomatic Carotid Plaques in RA Patients Are Associated with Increased HDL Function
Silvia Rollefstad¹, Bente Halvorsen², Tonje Skarpengland², Sella Provan³, Tore K. Kvien⁴ and Anne Grete Semb¹, ¹Preventive Cardio-Rheuma clinic, Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ²Research Institute of Internal Medicine, Oslo University Hospital Rikshospitalet, Oslo, Norway, ³Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁴PsAID taskforce, EULAR, Zurich, Switzerland
Background/Purpose Reverse cholesterol transport (RCT) is a major anti atherogenic function of high density lipoprotein cholesterol (HDL) and has been shown to be related to…
Abstract Number: 1141 • 2014 ACR/ARHP Annual Meeting
Comparisons of Quality of Life, Resource Use and Physical Functioning in RA Patients Classified As High, Moderate or Low Risk for Rapid Radiographic Progression
E Alemao¹, S Joo², P Allison³, M Al⁴, M Rutten-van Molken⁴, S Banerjee¹, C Iannaccone⁵, M Frits⁵, N Shadick⁵, M Weinblatt⁵ and Katherine Liao⁶, ¹Bristol-Myers Squibb, Princeton, NJ, ²Bristol-Myers Squibb, Hopewell, NJ, ³University of Pennsylvania, Philadelphia, PA, ⁴Erasmus University, Rotterdam, Netherlands, ⁵Brigham and Women's Hospital, Boston, MA, ⁶Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA
Background/Purpose: We developed and validated a prognostic model to identify subjects with elevated risk of rapid radiographic progression (RRP). The objective of this study was…
Abstract Number: 486 • 2014 ACR/ARHP Annual Meeting
Tofacitinib Improves Arterial Stiffness Despite up-Regulating Serum Cholesterol with Chronic Cardiovascular Disease in Methotrexate-Resistant Active Rheumatoid Arthritis Patients. a Cohort Study
Kensuke Kume¹, Kanzo Amano², Susumu Yamada², Toshikatsu Kanazawa³, Hiroshi Komori⁴, Kazuhiko Hatta⁵, Kuniki Amano⁶ and Noriko Kuwaba⁷, ¹20-16 Higashi Kannon, Nishi Ward, hiroshima clinic, Hiroshima, Japan, ²Rheumatology, Hiroshima Clinic, Hiroshima, Japan, ³rheumatology, hiroshima clinic, hiroshima, Japan, ⁴internal medicine, hiroshima clinic, hiroshima, Japan, ⁵Rheumatology, Hatta Clinic, Kure, Japan, ⁶Rheumatology, Sky Clinic, Hiroshima, Japan, ⁷Medical Research, Sanki Clinical Link, Hiroshima, Japan
Background/Purpose: Patients with rheumatoid arthritis (RA) have an increased cardiovascular (CV) risk. We should have strategies for primary cardiovascularprevention in RA. Tofacitinib (Tofa) could possibly…
Abstract Number: 2203 • 2014 ACR/ARHP Annual Meeting
Adalimumab Therapy Improves Insulin Sensitivity in Non-Diabetic Psoriatic Patients: A 6-Month Prospective Study
Trinitario Pina Murcia¹, Raquel López-Mejías¹, Fernanda Genre¹, Begoña Ubilla¹, Susana Armesto², Marcos A. González-López², María del Carmen Gonzalez-Vela³, Javier Llorca⁴, Ricardo Blanco⁵ and MA González-Gay¹, ¹Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Rheumatology Division, IDIVAL, Santander, Spain, ²Dermatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ³Dept. of Pathology, Hospital Universitario Marqués de Valdecilla, Universidad de Cantabria, Santander, Spain, ⁴Department of Epidemiology and Computational Biology, School of Medicine, University of Cantabria, and CIBER Epidemiología y Salud Pública (CIBERESP), IDIVAL, Santander, Spain, ⁵Hospital Marques de Valdecilla, Santander, Spain
Background/Purpose: psoriasis is a systemic inflammatory condition that shares similarities with other inflammatory immune disorders. In this context, patients with psoriasis are at an increased…
Abstract Number: 1437 • 2014 ACR/ARHP Annual Meeting
Cholesterol Efflux Capacity of HDL and Coronary Atherosclerosis in Rheumatoid Arthritis
Michelle J. Ormseth¹, Patricia Yancey², Suguru Yamamoto², Annette M. Oeser¹, Tebeb Gebretsadik³, Ayumi Shintani¹, MacRae F. Linton¹, Sergio Fazio¹, Sean Davies¹, L Jackson Roberts II¹, Kasey C. Vickers¹, Paolo Raggi⁴, Valentina Kon¹ and C Michael Stein¹, ¹Vanderbilt University, Nashville, TN, ²Medicine, Vanderbilt University, Nashville, TN, ³Biostatistics, Vanderbilt University, Nashville, TN, ⁴Emory University, Atlanta, GA
Background/Purpose: Cardiovascular (CV) risk is increased in patients with rheumatoid arthritis (RA), but not fully explained by traditional risk factors such as LDL and HDL…
Abstract Number: 1064 • 2014 ACR/ARHP Annual Meeting
Unique Profile of Cardiovascular Risk Factors in Rheumatoid Arthritis High-Risk Populations with Insufficient Risk Control
Ulf Müller-Ladner¹, Stefan Kleinert², Klaus Krüger³, Bianca Wittig⁴ and Rolf Hecker⁴, ¹Rheumatologie und klinische Immunologie, Kerckhoff-Klinik GmbH, Abt. Rheumatologie und klinische Immunologie, Bad Nauheim, Germany, ²Rheumatologie, Praxisgemeinschaft Rheumatologie-Nephrologie, Rheumatologische Schwerpunktpraxis, Erlangen, Germany, ³Praxiszentrum St. Bonifatius, München, Germany, ⁴Abbvie Deutschland GmbH & Co. KG, Wiesbaden, Germany
Background/Purpose More than 50% of premature deaths in patients with rheumatoid arthritis (RA) are due to cardiovascular disease (CVD). Both the cumulative burden of inflammation…
Abstract Number: 392 • 2014 ACR/ARHP Annual Meeting
Neuroendocrine Hormone and Metabolic Peptide Levels in the Earliest Phases of Rheumatoid Arthritis – Do Free Fatty Acids Play a Role?
Man Wai Tang¹, Frieda A. Koopman², Jan P.M. Visscher², Marjolein J.H. de Hair², Danielle M. Gerlag^2,3 and Paul P. Tak^2,4, ¹Division of Clinical Immunology and Rheumatology & Department of Experimental Immunology, Academic Medical Center / University of Amsterdam, Amsterdam, Netherlands, ²Division of Clinical Immunology and Rheumatology, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, ³GlaxoSmithKline, Cambridge, United Kingdom, ⁴University of Cambridge, Cambridge and GlaxoSmithKline, Stevenage, United Kingdom
Background/Purpose: Rheumatoid arthritis (RA) is a chronic autoimmune disease associated with several neuroendocrine hormones and metabolic peptides. The crosstalk between the hormones and the immune…
Abstract Number: 2936 • 2014 ACR/ARHP Annual Meeting
Is Ankylosing Spondylitis a Risk Factor for Cardiovascular Diseases, and How Does These Risks Compare to Those in Rheumatoid Arthritis?
Johan Askling¹, Lennart Jacobsson² and Jonas Eriksson¹, ¹Clinical Epidemiology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, ²sahlrenska academy, gothenburg, Sweden
Background/Purpose Patients with RA are at increased risk of cardiovascular (CV) diseases, including acute coronary syndromes (ACS), deep venous thromboembolism (DVT) and pulmonary embolism (PE),…
Abstract Number: 2103 • 2014 ACR/ARHP Annual Meeting
Benefits of Early Onset of DAS28 (CRP) <2.6 on Physical Functioning, Quality of Life and Resource Use Among RA Patients in a Clinical Practice Setting
E Alemao¹, S Joo², H Kawabata¹, S Banerjee¹, M Frits³, C Iannaccone³, N Shadick³ and M Weinblatt³, ¹Bristol-Myers Squibb, Princeton, NJ, ²Bristol-Myers Squibb, Hopewell, NJ, ³Brigham and Women's Hospital, Boston, MA
Background/Purpose: Guidelines in RA recommend that treatment should be aimed at reaching a target of remission or low disease activity (LDA) as soon as possible,…
Abstract Number: 1413 • 2014 ACR/ARHP Annual Meeting
The Prevalence of Renal Impairment in Patients with Rheumatoid Arthritis
Marion Couderc Sr.¹, Martin Soubrier², Bruno Pereira³, Aurelien Tiple⁴, Melanie Gilson⁵, Bruno Fautrel⁶, Sophie Pouplin⁷, Emmanuelle Dernis Labous⁸, Laure Gossec⁹, Cécile Gaujoux-Viala¹⁰ and Maxime Dougados¹¹, ¹Chu G.Montpied, Clermont Ferrand, France, ²Rheumatology, CHU G.-Montpied, Clermont-Ferrand, France, ³Clinical research department, Clermont-Ferrand, France, ⁴Nephrology, CHU, Clermont-Ferrand, France, ⁵Rheumatology, CHu Grenoble, Grenoble, France, ⁶Rheumatology, Pitie Salpetriere Hospital, Paris, France, ⁷Rheumatology, Rouen University Hospital, Rouen, France, ⁸Rhumatologie, Ch Du Mans, Le Mans, France, ⁹Rheumatology, UPMC GRC08, Paris 06 University, Pitié Salpétrière Hospital, Paris, France, ¹⁰EA 2415, Montpellier I University, Nîmes University Hospital, Rheumatology Department, Nîmes, France, ¹¹Université Paris René Descartes and Hôpital Cochin, Paris, France
Background/Purpose: To assess the prevalence and associations of renal dysfunction in patients with rheumatoid arthritis (RA). Methods: COMEDRA is a French nationwide cross-sectional multicentre study…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].